Poland's industry association elects new management
This article was originally published in Scrip
Poland's association of research-based companies, Infarma, has elected a new management board for a two-year term. Jerzy Toczyski of GlaxoSmithKline has become its president and Peter Koetsier of Bristol-Myers Squibb its vice-president. Jaroslaw Lange of Amgen, Marynika Woroszylska-Sapieha of Sanofi-Aventis, Patrick van Ginneken of Pfizer and Lukasz Zybaczynski of MSD were elected board members, while Donald Bellamy of Novartis was appointed Infarma's treasurer.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.